



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

NYC

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/528,644	03/20/2000	Lars Thim	3951.224-US	5698
23650	7590	01/19/2005	EXAMINER	
NOVO NORDISK, INC. PATENT DEPARTMENT 100 COLLEGE ROAD WEST PRINCETON, NJ 08540			ROMEO, DAVID S	
			ART UNIT	PAPER NUMBER
			1647	

DATE MAILED: 01/19/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No.	Applicant(s)
	09/528,644	THIM ET AL.
Examiner	Art Unit	
David S Romeo	1647	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 03 November 2004.  
 2a) This action is FINAL.                            2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 66 and 67 is/are pending in the application.  
 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 66 and 67 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
     1. Certified copies of the priority documents have been received.  
     2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
     3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: _____

**DETAILED ACTION**

The amendment filed 11/03/2004 has been entered. Claims 66 and 67 are pending and being examined. The double patenting rejection is no longer applicable to the present claims.

5

**New Formal Matters, Objections, and/or Rejections:*****Claim Rejections - 35 USC § 103***

Claim 66 is rejected under 35 U.S.C. 103(a) as being unpatentable over

Tomasetto (2, cited by Applicants) in view of Hitzeman (X, the paper mailed

10 07/20/2001), Onda (the paper mailed 07/20/2001), Strausberg (the paper mailed  
05/03/2004), Gelfand (the paper mailed 05/03/2004), and Grinna (U, the paper mailed  
01/2005).

Tomasetto discloses the cDNA and deduced amino acid sequence of a human spasmolytic polypeptide (hSP) (paragraph bridging pages 409-410; Figure 5). The  
15 encoded protein contains a putative signal sequence, amino acids 1-24 (Figure 5). The  
amino acid sequence of the encoded protein minus the putative signal peptide is identical  
to SEQ ID NO:1 of the present claims, as indicated below (Qy = Applicants' SEQ ID  
NO: 1) (Db = hSP):

20 RESULT 1  
ENTRY S12371 #type fragment  
TITLE spasmolytic protein 1 precursor - human (fragment)  
ALTERNATE NAMES trefoil factor 2  
ORGANISM #formal\_name Homo sapiens #common\_name man  
DATE 21-Nov-1993 #sequence\_revision 24-May-1996 #text\_change  
18-Sep-1998  
25 ACCESSIONS S12371  
REFERENCE S12371  
#authors Tomasetto, C.; Rio, M.C.; Gautier, C.; Wolf, C.; Hareveni,  
M.; Chamson, P.; Lathe, R.  
30 #journal EMBO J. (1990) 9:407-414  
#title hSP, the domain-duplicated homolog of pS2 protein, is  
co-expressed with pS2 in stomach but not in breast  
carcinoma.  
35 #cross-references MUID:90151615  
#accession S12371

Art Unit: 1647

```

##molecule_type mRNA
##residues 1-130 ##label TOM
##cross-references EMBL:X51698; NID:g36558; PID:g36559
5 GENETICS
#gene GDB:TFF2; SML1
##cross-references GDB:128989; OMIM:182590
#map_position 21q22.3
FUNCTION
#description inhibits gastrointestinal motility and gastric acid secretion
10 CLASSIFICATION #superfamily spasmolytic protein; trefoil homology
KEYWORDS duplication; hormone; pancreas
FEATURE
1-24 #domain signal sequence (fragment) #status predicted
#label SIG\
15 25-130 #product spasmolytic protein #status predicted #label
#label MAT\
32-73 #domain trefoil homology #label TRF1\
82-122 #domain trefoil homology #label TRF2\
20 30-128,32-59,43-58,
53-70,82-108,
92-107,102-119 #disulfide_bonds #status predicted
SUMMARY #length 130 #checksum 8997

25 Query Match 100.0%; Score 857; DB 1; Length 130;
Best Local Similarity 100.0%; Pred. No. 6.82e-177;
Matches 106; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Db 25 EKPSPCQCSRLSPHNRNTNCGFPGITSDQCFDNGCCFDSSVTGVPWCFHPLPKQESDQCVM 84
30 Qy 1 EKPSPCQCSRLSPHNRNTNCGFPGITSDQCFDNGCCFDSSVTGVPWCFHPLPKQESDQCVM 60
Db 85 EVSDRRNCGYPGISPEECASRKCCFSNIFEVWPWCFPPNSVEDCHY 130
Qy 61 EVSDRRNCGYPGISPEECASRKCCFSNIFEVWPWCFPPNSVEDCHY 106.
35

```

hSP contains the amino acid sequence Asn-X-Ser/Thr, wherein X is any amino acid, at amino acid residues 39-41, which is a classic N-linked glycosylation site, as evidenced by Hitzeman. Specifically, Hitzeman teaches N-linked glycosylation at the amino acid sequence Asn-X-Ser/Thr wherein X is any amino acid (page 436, full paragraph 2). Amino acid residues 39-41 of hSP correspond to amino acids 15-17 of Applicants' SEQ ID NO:1. Tomasetto discloses strong conservation of primary structure between PSP, mSP and hSP which suggest that these three proteins fulfill similar biological functions (page 412, column 2, full paragraph 4). Tomasetto suggests purifying hSP (page 413, left column, last paragraph of discussion). Tomasetto does not teach, in the sense that Tomasetto does not anticipate, an isolated hSP polypeptide which has an amino acid sequence according to SEQ ID NO: 1 and which is N-glycosylated with (GlcNAc)<sub>2</sub>(Man)<sub>10-15</sub> at the Asn in position 15 of SEQ ID NO: 1.

Onda discloses a polypeptide having high homology with pancreatic spasmolytic polypeptide (PSP) and expects it to fulfill similar biological functions (page 6, full paragraph 3). Onda discloses the expression and secretion of the recombinant human polypeptide in *E. coli*, yeast cells, and animal cells (page 3, full paragraph 1; page 4, line 5 55; sentence bridging pages 4-5; page 5, lines 8-9 and 31-34; Example 5, pages 9-10).

The use of yeasts such as *Saccharomyces* as hosts for expressing mammalian and other foreign proteins offers advantages lacking in more commonly used prokaryotic hosts such as *Escherichia coli*. See Strausberg, column 1, full paragraph 2.

Mammalian cells are more difficult to culture than yeast. See Gelfand, column 2, 10 lines 29-30.

Grinna teaches that on heterologous invertase produced in *P. pastoris*, approximately 85% of the oligosaccharides are in the size range  $\text{Man}_{8-14}\text{GlcNAc}_2$ . The largest oligosaccharides isolated from *P. pastoris* are significantly shorter than the hypermannosylated structures typical of *S. cerevisiae*, indicating that the factors which 15 influence the processing of N-linked oligosaccharides in *P. pastoris* are different from those which influence processing in *S. cerevisiae*. The smaller N-linked oligosaccharides synthesized by *P. pastoris* resemble high-mannose oligosaccharides synthesized by animal cells, and this finding increases the utility of *P. pastoris* as a host for the production of heterologous glycoproteins. See the Abstract.

20 Onda, Strausberg, Gelfand, and Grinna do not teach an isolated hSP polypeptide which has an amino acid sequence according to SEQ ID NO: 1 and which is N-glycosylated with  $(\text{GlcNAc})_2(\text{Man})_{10-15}$  at the Asn in position 15 of SEQ ID NO: 1.

However, it would have been obvious to one of ordinary skill in the art at the time of Applicants' invention to purify hSP, as suggested by Tomasetto, and to modify that teaching by expressing hSP recombinantly in *P. pastoris*, as taught by Grinna, with a reasonable expectation of success. One of ordinary skill in the art would be motivated to

5 make this modification because the supply of many eukaryotic proteins which have potential clinical or industrial use is often limited by their low natural availability. Gene cloning and expression in (*E. coli*, bacteria, yeast, etc.) would provide a more abundant source of these polypeptides. One of ordinary skill in the art would be motivated to combine these teachings because the advantages of recombinant expression would

10 provide a convenient source of readily purified protein. One of ordinary skill in the art would be motivated to use yeast for the recombinant expression of hSP because the use of yeasts such as *Saccharomyces* as hosts for expressing mammalian and other foreign proteins offers advantages lacking in more commonly used prokaryotic hosts such as *Escherichia coli* and because mammalian cells are more difficult to culture than yeast..

15 One of ordinary skill in the art would be motivated to use *P. pastoris* for the expression of hSP because the largest oligosaccharides isolated from *P. pastoris* are significantly shorter than the hypermannosylated structures typical of *S. cerevisiae* and because the smaller N-linked oligosaccharides synthesized by *P. pastoris* resemble high-mannose oligosaccharides synthesized by animal cells, and this finding increases the utility of *P.*

20 *pastoris* as a host for the production of heterologous glycoproteins. In so doing one of ordinary skill in the art would reasonably expect to obtain an isolated hSP polypeptide which has an amino acid sequence according to SEQ ID NO: 1 and which is N-glycosylated with (GlcNAc)<sub>2</sub>(Man)<sub>8-14</sub> at the Asn in position 15 of SEQ ID NO: 1. The

claimed  $\text{Man}_{10-15}\text{GlcNAc}_2$  overlaps the  $\text{Man}_{8-14}\text{GlcNAc}_2$  disclosed by the prior art. In the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a *prima facie* case of obviousness exists. See M.P.E.P. 2144.05(I). The invention is *prima facie* obvious over the prior art.

5

Claims 66 and 67 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tomasetto (2, cited by Applicants) in view of Hitzeman (X, the paper mailed 07/20/2001), Onda (the paper mailed 07/20/2001), Strausberg (the paper mailed 05/03/2004), Gelfand (the paper mailed 05/03/2004), and Grinna (U, the paper mailed 10 01/2005) as applied to claim 66 above and further in view of Jorgensen (U, the paper mailed 05/03/2004).

Tomasetto in view of Hitzeman, Onda, Strausberg, Gelfand, and Grinna teach an isolated hSP polypeptide which has an amino acid sequence according to SEQ ID NO: 1 and which is N-glycosylated with  $(\text{GlcNAc})_2(\text{Man})_{8-14}$  at the Asn in position 15 of SEQ 15 ID NO: 1. Tomasetto in view of Hitzeman, Onda, Strausberg, Gelfand, and Grinna do not teach a pharmaceutical composition comprising an isolated hSP polypeptide which has an amino acid sequence according to SEQ ID NO: 1 and which is N-glycosylated with  $(\text{GlcNAc})_2(\text{Man})_{8-14}$  at the Asn in position 15 of SEQ ID NO: 1 together with a pharmaceutically acceptable carrier or excipient.

20 Jorgensen teaches a pharmaceutical composition comprising PSP and a pharmaceutically acceptable carrier (page 232, full paragraphs 1 and 2; page 233, full paragraph 2; paragraph bridging pages 233-234; page 234, full paragraph 1). PSP inhibits gastrointestinal motility and gastric acid secretion (page 231, full paragraph 1).

PSP is atoxic and effective after oral administration. PSP may possess a potential utility in the treatment of gastro-duodenal ulcer diseases. Page 243, full paragraph 1. Jorgensen does not teach an isolated hSP polypeptide which has an amino acid sequence according to SEQ ID NO: 1 and which is N-glycosylated with  $(\text{GlcNAc})_2(\text{Man})_{8-14}$  at the Asn in 5 position 15 of SEQ ID NO: 1.

However, it would have been obvious to one of ordinary skill in the art at the time of Applicants' invention to make an isolated hSP polypeptide which has an amino acid sequence according to SEQ ID NO: 1 and which is N-glycosylated with  $(\text{GlcNAc})_2(\text{Man})_{8-14}$  at the Asn in position 15 of SEQ ID NO: 1, as taught by Tomasetto 10 in view of Hitzeman, Onda, Strausberg, Gelfand, and Grinna, and to modify that teaching by making a pharmaceutical composition, as taught by Jorgensen, with a reasonable expectation of success. One of ordinary skill in the art would be motivated to combine these teachings because PSP, mSP and hSP display a strong conservation of primary 15 structure, which suggest that these three proteins fulfill similar biological functions, because PSP may possess a potential utility in the treatment of gastro-duodenal ulcer diseases, and it would have been obvious to one of ordinary skill in the art at the time of 20 Applicants' invention to test the potential utility of hSP in the treatment of gastro-duodenal ulcer diseases. The invention is *prima facie* obvious over the prior art.

20

***Response to Arguments***

Applicants argue that there is nothing in the cited art that teaches that the  $(\text{GlcNAc})_2(\text{Man})_{10-15}$  structure might be attached to the Asn 15 of SEQ ID NO: 1 upon recombinant expression in yeast. Applicant's arguments have been fully considered but

Art Unit: 1647

they are not persuasive. The claimed  $\text{Man}_{10-15}\text{GlcNAc}_2$  structures overlaps the  $\text{Man}_8\text{-}_{14}\text{GlcNAc}_2$  structures disclosed by the prior art. In the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a *prima facie* case of obviousness exists. See M.P.E.P. 2144.05(I). The examiner believes he has addressed all pertinent

5 arguments.

### ***Conclusion***

No claims are allowable.

10 ANY INQUIRY CONCERNING THIS COMMUNICATION OR EARLIER COMMUNICATIONS FROM THE EXAMINER SHOULD BE DIRECTED TO DAVID S. ROMEO WHOSE TELEPHONE NUMBER IS (571) 272-0890. THE EXAMINER CAN NORMALLY BE REACHED ON MONDAY THROUGH FRIDAY FROM 7:30 A.M. TO 4:00 P.M. IF ATTEMPTS TO REACH THE EXAMINER BY TELEPHONE ARE UNSUCCESSFUL, THE EXAMINER'S SUPERVISOR, BRENDA BRUMBACK, CAN BE REACHED ON (571) 272-0961.

15 IF SUBMITTING OFFICIAL CORRESPONDENCE BY FAX, APPLICANTS ARE ENCOURAGED TO SUBMIT OFFICIAL CORRESPONDENCE TO THE CENTRAL FAX NUMBER FOR OFFICIAL CORRESPONDENCE, WHICH IS (571) 273-8300.

CUSTOMERS ARE ALSO ADVISED TO USE CERTIFICATE OF FACSIMILE PROCEDURES WHEN SUBMITTING A REPLY TO A NON-FINAL OR FINAL OFFICE ACTION BY FACSIMILE (SEE 37 CFR 1.6 AND 1.8).

FAXED DRAFT OR INFORMAL COMMUNICATIONS SHOULD BE DIRECTED TO THE EXAMINER AT (571) 273-0890.

20 ANY INQUIRY OF A GENERAL NATURE OR RELATING TO THE STATUS OF THIS APPLICATION OR PROCEEDING SHOULD BE DIRECTED TO THE GROUP RECEPTIONIST WHOSE TELEPHONE NUMBER IS (703) 308-0196.



DAVID ROMEO  
PRIMARY EXAMINER  
ART UNIT 1647

25 DSR  
JANUARY 18, 2005